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Abstract Endovascular abdominal and thoracic aortic
aneurysm repair and are widely used to treat increasingly
complex aneurysms. Secondary endoleaks, defined as those
detected more than 30 days after the procedure and after
previous negative imaging, remain a challenge for aortic
specialists, conferring a need for long-term surveillance
and reintervention. Endoleaks are classified on the basis of
their anatomic site and aetiology. Type 1 and type 2
endoleaks (EL1 and EL2) are the most common endoleaks
necessitating intervention. The management of these
requires an understanding of their mechanics, and the risk
of sac enlargement and rupture due to increased sac pres-
sure. Endovascular techniques are the main treatment
approach to manage secondary endoleaks. However, sur-
gery should be considered where endovascular treatments
fail to arrest aneurysm growth. This chapter reviews the
aetiology, significance, management strategy and tech-
niques for different endoleak types.
Fact Sheet
A: Ten Most Important Points Regarding Secondary
Endoleak Management Following TEVAR
and EVAR
1. CTA is the main imaging investigation for assessing
and characterising secondary endoleaks.
2. EL1 endoleaks are high pressure and require prompt
treatment.
3. The main endovascular therapeutic options for EL1
include EndoAnchors, aortic cuffs and embolisation.
4. EL2 are low pressure, often benign and only warrant
treatment if associated with a sac size increase of at
least 5 mm.
5. An occult EL1 and EL3 should be considered and
excluded when facing a suspected EL2 with increas-
ing sac size.
6. Embolisation is the mainstay treatment for EL2 with
increasing sac size
7. Techniques for catheterising the endoleak sac in EL2
include transarterial, transiliac paraendograft, direct
sac puncture and transcaval embolisation.
8. Embolisation agents for both EL1 and EL2 emboli-
sation include coils, and liquid embolics, including
Onyx, glue and thrombin.
9. The outcomes of type 2 embolisation in experienced
hands are very good if experts select the appropriate
embolisation method for the specific patient anatomy
and perform a technically complete embolisation.
10. Embolisation has a small but defined role in the
management of endoleaks after TEVAR.
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B: Five Most Important Numbers with Respect
to Endoleak Management After EVAR and TEVAR
11. The combined approach of DUS, CTA and MRI
detects and characterises secondary endoleaks in 91%
of cases.
12. Embolisation has a technical success above 95% and
mid-term success of 80% for EVAR EL1a.
13. Embolisation of type 2 endoleaks is indicated for an
increase in sac size of 5 mm on sequential imaging.
14. Regarding outcomes of embolisation for type 2
endoleaks, a recent review indicated that the technical
success rate for direct sac puncture embolisation
(81%) is higher than transarterial embolisation (63)
and a lower rate of recurrence (19% vs 36%).
15. Type 1 endoleaks occur in 3.3–16% after TEVAR,
and type 2 endoleaks occur in 3.3% of all TEVAR
cases. Embolisation of left subclavian artery associ-
ated type 2 endoleaks has a technical and clinical
success of 100%.
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D: Two Messages About Endoleak Management
Following TEVAR and EVAR
1. The primary therapy for type 1, 2 and 3 endoleaks
after EVAR and TEVAR involves endovascular methods
in the majority of cases. Many of the therapeutic options
require the insertion of additional endografts in con-
junction with additional endovascular methods, e.g.
EndoAnchors, chimneys, etc.
2. Embolisation plays a key role in the treatment of type
2 endoleaks and EVAR and TEVAR. Embolisation plays
a small, but significant role in the management of
challenging type 1 endoleaks after EVAR and TEVAR if
no other endovascular solution is feasible.
E: Prediction for the Next Five Years
The therapeutic algorithm for all endoleaks will continue as
described in this manuscript. It would be surprising to see
any significant therapeutic advances or change in the
approach to the management of any of the endoleak types.
However, with increasing recognition that treating patients
with hostile proximal necks by standard EVAR, and with
the potential ramifications of planned UK NICE EVAR
guidelines, we may see a significant reduction in the fre-
quency of type 1a endoleaks after EVAR.
Introduction
Endovascular abdominal and thoracic aortic aneurysm
repair (EVAR) and (TEVAR) have become the mainstay of
therapy of many pathologies of the abdominal and thoracic
aorta. Moreover, the development of complex endograft
technologies such as fenestrated EVAR (FEVAR), bran-
ched EVAR (BEVAR) and parallel grafts enables
increasingly challenging anatomy to be treated. However,
despite the increased number of procedures and diversity of
techniques, the management of endoleaks remains a chal-
lenge for aortic specialists. Endoleaks (EL) may compro-
mise long-term endograft viability and some are associated
with an increased risk of rupture, thereby necessitating
long-term surveillance and secondary interventions. Thus,
early detection and classification of endoleaks is crucial for
optimal management planning. Endoleaks may be classi-
fied as primary or secondary endoleaks. Primary endoleaks
appear within 30 days post-procedure and secondary (or
late) endoleaks are detected more than 30 days after the
procedure and after previous negative imaging. Endoleaks
are also classified on the basis of their anatomic site and
aetiology and are subdivided into five types (Table 1) [1].
Type 1 endoleak (EL1) is caused by inadequate apposition
of the endograft to the vessel wall (attachment site) and is
subclassified as EL 1a for proximal endoleak, EL 1b for
distal attachment site endoleak and EL Ic for lack of seal
by an iliac occlude plug in aorto-uni-iliac repair with a
crossover graft; type 2 endoleak (EL2) involves perfusion
of the aneurysm sac from collateral vessels; type 3 endo-
leak (EL3) describes stent graft component separation or
endoleak due to a fabric tear; type 4 endoleak (EL4) rep-
resents an endoleak due to porosity of the graft; and type 5
endoleak (EL5), also known as endotension, is present
when there is expansion of the sac without an apparent
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endoleak on imaging. With developments in endograft
fabric technology, type 4 endoleaks are of historical value
and will not be further described. A wide range of treat-
ment options exist including transarterial embolisation,
percutaneous direct sac puncture embolisation, transcaval
embolisation, surgical and conservative management. The
criteria for best management should be tailored to each
individual patient after careful planning and multidisci-
plinary team discussion.
This article is focused on the diagnosis and management
of secondary type 1, 2 and 3 endoleaks after EVAR and
TEVAR.
Diagnosis of Secondary Endoleaks
Numerous imaging modalities are available to detect and
characterise endoleaks. However, factors such as the
patient’s BMI, anatomy, endoleak type and size, local
expertise and costs play a role in deciding optimal imaging
follow-up protocols.
CT angiography (CTA) appears to be the gold standard
for the diagnosis of both thoracic and abdominal endoleaks.
The technique is probably optimal when a pre-contrast scan
followed by an arterial and delayed phase study is per-
formed, with endoleaks best appreciated on the delayed
phase imaging [2, 3]. However, due to increase radiation
exposure and cost considerations [4], usually an arterial
phase or a dual bolus scan is sufficient to depict the endoleak.
Our institution primarily employs a single arterial phase
protocol for standard EVAR and TEVAR follow-up, with
dual and triple phase imaging reserved for problem solving.
Doppler and contrast-enhanced ultrasound (CEUS) are
commonly used in surveillance after EVAR, providing an
accessible and affordable modality, with no radiation and
high accuracy when performed by an experienced operator.
Similarly, contrast-enhanced MRI/MRA does not
expose the patient to ionising radiation. In some patients,
contrast-enhanced MRI appears to be superior to CTA to
demonstrate occult endoleaks Nevertheless, MRI is not
included in routine follow-up protocols due to the high
costs, the prolonged examination time, the restricted
availability and the common use of MR-incompatible
endografts.
Conventional catheter angiography and/or C-Arm CTA
(e.g. DynaCT—Siemens, Germany) is used as a problem-
solving tool when an endoleak cannot be classified, or if
there is a sac size increase without a visible endoleak on
non-invasive imaging. In practice, catheter angiography is
seldom positive in these latter cases.
The combined approach of DUS, CTA and MRI can
raise the detection rate of endoleaks to 91% [5]. However,
the necessary lifelong surveillance of this patient group
increases the costs of aortic repair by 50% [4]. State-of-the-
art imaging is crucial to guide optimal management for
EVAR and TEVAR complications, especially endoleaks.
Management of Secondary Endoleaks—EVAR
1. Type 1 Endoleaks
Type 1 endoleaks occur in up to 9% of cases [6] and is
recognised as an indication for reintervention due to the
high risk for rupture in up to 52% of cases [7, 8]. The risk
of rupture is even higher (3.37%) when there is a combi-
nation of high-pressure endoleaks EL1 and EL3. Type 1a
endoleaks are related to adverse proximal neck anatomy
and there is an increased risk of these as more challenging
Table 1 Summary of classification of endoleaks and their management
Endoleak Cause of sac perfusion Management
1 Flow from the proximal or distal graft attachment site Prompt
a Proximal graft attachment site Angioplasty, Palmaz or cuff extension, chimney extension and
embolisation
b Distal graft attachment site Angioplasty and extension of distal limb
c Endoleak at the site of an iliac occluder plug Insertion of an additional iliac occluder plug or embolisation
2 Retrograde flow through patent aortic side branch
vessels
Conservative if sac size stable Embolisation if sac size increase
3 Mechanical graft failure Prompt
a Modular disconnection Placement of additional endograft components
Leak at a fenestration, branch or visceral stent
b Fabric tear
4 Graft porosity Conservative. Transient phenomenon
5 Sac size increase with no visible endoleak May consider catheter angiography with cone beam CT
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aortic aneurysms are treated using endografts.. Secondary
EL1 occur in 2.2 to 15% [9, 10]. Early EL1a is a common
complication (30%) after snorkel/chimney EVAR tech-
nique, with high spontaneous resolution in up to 71.8% at
12 months and a low reintervention rate at 3.3% [11]. Late
EL1a has been reported in up to 7% of patients after
chimney EVAR [9].
Type 1b endoleak is caused by an inadequate seal at the
distal landing zone. Late type 1b endoleaks are reported in
2.3% at a mean follow-up of 32.8 months [10]. Similar to
EL1a, EL1b are associated with an increase in sac size and
aneurysm rupture.
Management of Type 1a Endoleak
Endovascular management of EL1a is mandatory, because
of the documented risk of rupture. Technical success rates
are high when managing intra-procedural or early EL1a, in
the order of 90–100% [12–14]. Multiple options for rein-
tervention are available, depending on the primary aortic
repair technique that was used and the appearance on
imaging. Standard techniques for primary endoleaks may
include balloon dilatation and the insertion of giant balloon
expandable stents in the neck to promote a proximal seal.
However, these are seldom useful in secondary EL1a.
Proximal endograft extension, either alone or in combina-
tion with chimney grafts, may be useful in selected patients
with appropriate anatomy. More complex management
options include FEVAR or BEVAR techniques. In addi-
tion, EndoAnchors (Medtronic, Santa Rosa, CA) provide
proximal fixation of the endograft to the aortic wall with
promising outcomes with technical success in 95%,
residual EL1a in 9.1% and freedom from reintervention in
94.4% of patients treated [15].
If patients do not respond, are unsuitable, or are unfit for
the above techniques, transcatheter embolisation is an
alternative approach that can be used to manage the EL1a.
Embolisation has an increased role for EL1a after ChE-
VAR because of the limited alternative options available.
Embolisation technique: The most common access for
the embolisation is the common femoral artery, although
alternative routes can be used such as the transradial [16]
and transbrachial routes [17–19].
The author’s preferred technique (Fig. 1) is through a
retrograde femoral approach to advance a 45 cm long, 6F
sheath (e.g. Destination, Terumo, Tokyo, Japan) to just
below the top end of the endograft. An angiogram is per-
formed from a flush catheter to depict the endoleak and to
exclude additional other endoleak types. A reverse curve
catheter (e.g. 5F Simmons; Cook Inc, Bloomington, Ind)
with a hydrophilic wire is used to access the perigraft
endoleak space. A dimethyl sulphoxide (DMSO) compat-
ible microcatheter (e.g. 2.7F Progreat [Terumo Corp],
Marathon or Echelon [Medtronic, Santa Rosa, Calif], or
2.95F PX SLIM [Penumbra, Alameda, Calif]) is advanced
coaxially into the endoleak cavity. An endoleakogram is
performed to better assess the size, geometry and the neck
size and location of the endoleak nidus. The endoleako-
gram also enables the interventionist to evaluate for the
presence of exit vessels, to find the best projection for the
C-arm to visualise the endoleaks and to also create a road
map for the embolisation procedure. Depending to the
anatomy of the endoleak nidus, embolisation is performed
using either ethylene vinyl alcohol copolymer (Onyx,
Fig. 1 EL1a embolisation. A Axial CT angiogram shows proximal
EL1 in patient with a Nellix endograft (arrow). B Aortic angiograms
confirm EL1a (arrow head). C Embolisation of the endoleak cavity
with coils and Onyx via a microcatheter following catheterisation of
the endoleak cavity with reverse shaped catheter (asterix). D Final
angiogram shows successful endoleak embolisation
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Medtronic, Santa Rosa, Calif) alone or a combination of
detachable coils (e.g. Ruby, Penumbra) and Onyx-34.
Completion aortography is performed to assess for residual
filling of the endoleak [20]. Complications are limited to
puncture site access site hematomas and non-target
embolisation with reflux of a small volume of the liquid
embolic agent into the aorta, which is seldom clinically
problematic.
Outcomes of embolisation: Embolisation is usually
successful with immediate technical success (TS)
approaching 100% in small series single-centre studies
after EVAR (22 & 25 patients), EVAS (7 patients) and
chimney (9 patients) techniques [21–25]. Reports indicate
successful embolisation can be achieved using coils, Onyx
or glue (N-butyl cyanoacrylate (NBCA)), or a combination
[26–28] (Table 2).
Management of Type 1b Endoleaks
In general, these are easier to treat than EL1a endoleaks.
Standard treatment consists of insertion of an additional
endograft distally to achieve a distal seal. If there is
insufficient space to extend to the origin of the internal iliac
artery (IIA), then it is necessary to extend endograft cov-
erage into the external iliac artery (EIA). The internal iliac
artery can be overstented or embolised depending on
whether there is a risk of a type 2 endoleak by covering the
IIA (e.g. if the common iliac artery (CIA) is aneurysmal).
Embolisation of the IIA can be performed with coils or
plugs. In a two-centre study from 2018, 35 late 1b endo-
leaks that were treated by endograft extension demon-
strated a 100% TS rate, 100% freedom from re-intervention
at a mean follow-up at 20 months and no requirement for
open surgical treatment [29]. Additional novel technologies
that allow the preservation of the IIA include iliac branched
devices and parallel grafts. Embolisation has a role in a
very small minority of patients if no other option is
available or feasible. However, in reality this situation is
very rare after EVAR as distal endograft extension, with or
without preservation of the IIA is feasible.
Summary of Secondary Type 1 Endoleaks After
EVAR
All current techniques available for managing EL1a,
whether complex endovascular techniques such as
FEVAR, BEVAR and ChEVAR, or simpler approaches
such as EndoAnchors, embolisation techniques, cuff and/or
Palmaz stent, demonstrate high technical and clinical suc-
cess rates when used with the proper indication. Emboli-
sation techniques, with success rates from 86 to 100%,
should be considered when there is insufficient neck length
for stent graft extension, when the other techniques have
failed, or when the patient is unfit for more complex
therapies. When primary treatment involved chimney
EVAR, embolisation techniques can be used as the first line
treatment for a persistent secondary type 1a endoleak.
2. Type 2 Endoleaks
Secondary type 2 endoleaks (EL2) are the most common
endoleaks following EVAR and remain the main cause of
repeat intervention [30]. They occur despite complete
exclusion of the aneurysm at the proximal and distal
attachment sites. Type 2 endoleaks are caused by retro-
grade blood flow into the sac from branches of the endo-
graft-covered native aorta or iliac vessels. There is usually
one dominant inflow artery, most commonly the IMA or a
lumbar artery, and often one or more outflow arteries.
Patency of the IMA and one or more lumbar arteries pre-
EVAR, as well as larger aneurysms and aneurysms with
significant thrombus burden in the sac have found to
increase the risk of developing type 2 endoleaks [31, 32].
Below, we will address the best approach to management
of secondary type 2 endoleaks.
Indications for intervention in Secondary Type 2
Endoleaks
Whether to intervene or not and the exact point in time
when to intervene for EL2 are a topic of ongoing debate
[32–35]. EL2 are inherently low flow and are often tran-
sient, resolving following thrombosis of the aneurysm sac
and reversal of anticoagulation. A recent meta-analysis of
four major EVAR trials including 2783 patients showed an
EL2 incidence of 11.7%, a reintervention rate of 22% for
these EL2 (99 of 435 detected EL2); and no evidence that
EL2, whether treated or not treated were associated with
worse survival [36]. In fact the risk of aneurysm rupture in
the presence of an isolated type 2 endoleak is exceptionally
low [33]. The current consensus is that one should treat a
persistent EL2 when they are associated with a significant
sac size increase, commonly considered as at least 5 mm
over 6 months [37]. In the absence of an enlarging sac size,
patients with type 2 endoleak should be kept under follow-
up imaging by CTA or US based on standard local
protocols.
Embolisation is the main treatment for EL2. The aim of
intervention is to obliterate the endoleak cavity, which is
analogous to the central nidus in a vascular malformation.
This is best achieved by occlusion of the supplying arteries
(e.g. IMA) as well as the endoleak cavity. There are a
variety of embolisation techniques depending on the anat-
omy of the artery supplying the endoleak and the available
route to access the endoleaks.
Transarterial Embolisation
Secondary Endoleak Management Following TEVAR and EVAR
123
The most common technique is transarterial catheteri-
sation of the dominant feeding vessel via communicating
arteries supplying the vessel. This approach is performed
under conscious sedation and requires an accessible route
from an aortoiliac vessel, via collaterals to the vessel
feeding the endoleak and ideally the endoleak cavity itself.
The technical success of this approach is limited if the
responsible feeding vessel cannot be cannulated or if a
viable path to the endoleak cavity cannot be found.
Transarterial embolisation is most successful for endoleaks
originating from the IMA (Fig. 2). For embolisation of
IMA endoleaks, a long 6-F sheath is inserted via a common
Table 2 Main publications on outcomes of EL1 embolisation
Years Authors Pt Treatment Embolic Material Technical
success (%)
Mean
follow-up
(months)
Clinical
success
(%)
2018 Ierardi et al.
[43]
8 Embolisation Onyx and coils in 3, NBCA and Onyx in 1, Onyx
and coils in 1
100 (8/8) 16.8 100 (8/
8)
2018 Stenson et al.
[44]
15 9 Embolisations 6
proximal
extensions
Onyx ? coils 100 9/9 36 –
2017 van de Ham
et al. [45]
40 17 Embolisations
13 OC 10 Ch-
EVAS
Onyx ± coils 96.5
(overall
EL1
treatment)
1–6 –
2017 Marcelin
et al. [23]
9 Embolisation Onyx ± coils 100 9/9 15.9 ± 11.36 89 8/9
2017 Ameli-
Renani
et al. [21]
25 Embolisation Onyx ± coils 100 (25/25) 10 80–85
2017 Graif et al.
[46]
8 Embolisation 6
ELIa, 2 ELIb
Onyx ± coils 88 (7/8) 6.9 71(5/7)
2015 Gandini et al.
[17]
1 Transcaval
Embolisation
Cuff Zenith (Cook Medical, Bloomington, Ind) and
thrombin and coils
100 (1/1) 12 100 (1/
1)
2014 Eberhardt
et al. [47]
8 Embolisation 6
ELIa, 1 ELIb, 1
ELIa & ELIb
Onyx ± coils 100 (8/8) 13.2 (8–24) 88 (7/8)
2013 Katada et al.
[48]
1 Embolisation and
cuff
Coils NBCA-lipiodol embolisation was performed
(B), then the Zenith TX2 extension cuff (Cook
Medical, Bloomington, Ind)
100 (1/1) 6 100 (1/
1)
2011 Henrikson
et al. [27]
6 Embolisation 5
ELIa, 1 ELIb
Onyx 100% (6/6) 3–18 100%
(6/6)
2011 Choi et al.
[49]
7 Embolisation and
cuff
N-BCA ± coils 86% (6/7) 18 (0–53 86% (6/
7)
2010 Lu et al. [50] 42 Embolisation 5
ELIa, 1 ELIb, 1
EL1a & ELIb
N-BCA or Onyx ± coils, fibrin glue injection 98% (41/42) 40 83%
(35/
42)
2010 Grisafi et al.
[51]
1 Onyx Embolisation device, Onyx (Micro Therapeutics
Inc, Irvine, Calif)
100% (1/1) 12 100%
(1/1)
2010 Loffroy et al.
[52]
1 Transarterial
microcoil
Embolisation
Detachable microcoils into the nidus while an intra-
aortic balloon catheter was inflated at the same
time
100% (1/1) 6 100%
(1/1)
2005 Golzarian
et al. [53]
32 Embolisation 32
ELIa
Coils with or without gelatin sponge or thrombin 91% (29/32) 38.6 91%
(20/
22)
2003 Maldonando
et al. [54]
17 Embolisation 13
ELIa, 4ELIb
10 n-BCA, 3 coils, 4 cuff 94% (16/17) 6.9 (0–19) 88%
(15/
17)
1999 Amesur et al.
[55]
5 Embolisation 1
ELIa, 4 ELIb
Coils 100% (5/5) 8 (3–17) 100%
(5/5)
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femoral artery access and the tip placed at the SMA origin.
A reverse-curve catheter (e.g. Simmons) is used to cathe-
terise the SMA and an angiogram is performed: a. to
confirm filling of the endoleak cavity via retrograde filling
of the IMA and b. to depict the route to the IMA via the
middle colic branch of the SMA and the left colic branch of
the IMA. The sheath is advanced into the SMA to provide
additional support. A hydrophilic 0.035 inch guidewire is
advanced into the middle colic artery, followed by the
selective catheter. A microcatheter is advanced coaxially
through the middle colic branches of the SMA, into the left
colic artery and subsequently into the IMA and the endo-
leak cavity. Embolisation is commonly performed using
liquid embolics including glue and Onyx, although use of
other agents such as gelfoam and thrombin have also been
reported. The authors prefer using either a liquid embolic
agent alone (Onyx or Glubran), or a combination of
pushable coils and a liquid embolic.
Type 2 endoleaks arising from iliolumbar arteries can be
treated in a similar manner (Fig. 3). The main difference to
the above is the use of a short 6-F sheath placed in the
ipsilateral femoral artery, using an appropriate catheter to
catheterise the internal iliac artery (e.g. Sos Omni) and
advancing a microcatheter coaxially via the ascending ili-
olumbar artery into the feeding lumbar artery or ideally the
endoleak cavity. A steerable sheath may be helpful in some
Fig. 3 Transarterial embolisation of type 2 endoleak arising from
iliolumbar artery. A Axial CT image shows endoleak arising from a
left lumbar artery (arrow). B Angiogram following catheterisation of
the left internal iliac artery shows filling of the endoleak cavity
(nidus) by the left lumbar artery (arrowhead). C Angiogram following
selective microcatheter catheterisation of the endoleak cavity through
the tortuous iliolumbar artery shows endoleak cavity (asterix) and
several exit vessels. D Complete embolisation of endoleak cavity and
exiting branches using Onyx
Fig. 2 Transarterial embolisation of type 2 endoleak. A Axial CT
image shows endoleak arising close to origin of IMA (arrow).
B Angiogram via microcatheter placed into middle colic branch of
SMA confirms endoleak (arrow head). C Microcatheter passed into
endoleak cavity via the left colic branch of the IMA, and embolisation
performed with Onyx. D Completion angiogram shows no further
filling of endoleak
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cases. This approach is more challenging with a lower
success rate compared to IMA endoleak embolisation,
because of the difficulty cannulating the responsible lum-
bar feeding vessel through the frequently tortuous and
small caliber arterio-arterial communications.
In these cases, if the endoleak cavity cannot be accessed,
it may be possible to successfully embolise the endoleak by
injecting a low viscosity Onyx preparation (Onyx 18) from
a more proximal location, which may flow gradually into
the endoleak cavity [38]. However, proximal embolisation
of the iliolumbar artery itself without occlusion of the
endoleak cavity may result in recurrence from other col-
lateral vessels that may supply the endoleak cavity.
Outcomes of transarterial embolisation: There is a rel-
atively wide spread of reported technical and clinical
success rates for this technique (Table 3), which is reflec-
ted in several meta-analysis and systemic reviews pub-
lished recently [36, 37, 39]. One of the largest single
cohorts published in 2012 of 95 patients undergoing 140
embolisation procedures (predominantly transarterial but a
few other techniques too), using a range of embolics (glue
61%, coils 29%, glue and coils 7% and Gelfoam 3%)
showed 81.5% freedom from aneurysm sac expansion at
one year but a significant decrease to 43.7% at five years,
with an associated increase in the number of repeat
embolisation procedures required [40]. The high long-term
failure rate may in part reflect failure to completely occlude
the endoleak cavity due to shortcomings of earlier tech-
niques such as embolising the feeding vessel but not the
endoleak cavity and performing embolisation using coils
alone without liquid embolic.
There is no consensus on the optimal embolic agent or
combination of embolic agents for transarterial
embolisation.
Where conventional transarterial embolisation is not
possible or fails, other techniques may achieve access to
the endoleak cavity for embolisation. These include tran-
siliac paraendograft embolisation (TIPE), direct sac punc-
ture and transcaval embolisation.
Transiliac Paraendograft Embolisation (TIPE)
TIPE is a novel technique for treating type 2 endoleaks
that cannot be accessed by the standard transarterial route
and involves passing a catheter and hydrophilic wire into
the potential space between the iliac limb endograft and the
vessel wall. Once access into the paraendograft space is
obtained, the catheter and wire are advanced superiorly
using standard catheter–guidewire manipulation techniques
between the graft and the artery wall until access to the sac
thrombus is achieved. Further catheter–guidewire manip-
ulation within the sac thrombus may enable the interven-
tionist to access the endoleak nidus itself, which is heralded
by blood flow from the catheter. After performing an
endoleakogram to define the anatomy of the endoleak, the
nidus and any visible and accessible feeding vessels are
embolised with a liquid embolic and coils or a combination
of these agents. This technique can be performed during
the same procedure as a failed attempt at conventional
transarterial embolisation.
Using this technique, Coppi and colleagues reported
successful embolisation of the sac in 16 of 17 patients [41]
using a 9F sheath, with one adverse event of a procedural
Table 3 Main publications on outcomes of EL2 transarterial embolisation, published since 2009
Authors No. of
endoleak
cases
Patient
population
Embolic material Technical
success
(%)
Follow-up
length mean–
months (range)
Clinical
success
(%)
Additional comments
Ribe et al.
[79]
18 600 Onyx 18 (100) 19 (3–60) 16 (89) EL2 source: IIA in 7, IMA in 7
and lumbar artery in 4 cases
Wojtaszek
et al.
[80]
22 22 Onyx 17 (77) 17 (3–38) 17/21 (81)
Hongo
et al.
[81]
20 20 NBCA and coils 18 (90) 18.5 (6–36) 13 (65)
Mu¨ller-
Wille
et al.
[82]
11 11 Onyx 6 (55) 26 (6–50) 8 (73) Clinical success defined as no
increase in sac size on
follow-up imaging
Funaki
et al.
[83]
16 25 Cyanoacrylate, coils and
ethylene vinyl alcohol
copolymer
14 (88) 27.5 (6–88) 16 (100) Clinical success defined as no
increase in sac size on
follow-up imaging
Internal iliac artery (IIA), Inferior mesenteric artery (IMA)
Secondary Endoleak Management Following TEVAR and EVAR
123
type Ib endoleak. In the authors experience, paraendograft
access with a 4/5Fr catheter alone or a 6Fr sheath is
technically adequate and minimises the risk of a procedural
type Ib endoleak [42]. In practice, procedural success is
limited by difficulty in accessing the paraendograft space
and accessing the endoleak nidus even when the sac
thrombus has been accessed. Embolisation of the sac
thrombus if the nidus cannot be accessed is of no benefit.
Direct Sac Puncture
This involves the direct percutaneous puncture of the
aneurysm sac. It is most commonly performed via a
translumbar approach with the patient positioned prone on
the operating table but may also be performed transab-
dominally [56] when there is an anterior endoleak. It can be
performed under general anaesthesia, or under sedation and
local anaesthesia, depending on the patient and the poten-
tial difficulty of the procedure. Prior CT imaging is initially
reviewed to assess the approach to the endoleak cavity.
Access is obtained using fluoroscopic guidance or targeted
C-arm CT software available on most modern angiographic
equipment. An 18 or 20G coaxial needle is advanced until
there is brisk, pulsatile blood flow through the needle,
indicating a satisfactory position within the endoleak cav-
ity. An angiogram is performed to depict the anatomy of
the endoleak and to plan the subsequent embolisation. At
this point, the needle is exchanged for a 4,5 or 6Fr sheath
over a stiff guidewire wire and a short selective catheter
(e.g. KMP, Bolia, Cobra) is advanced into the endoleak
cavity. With the catheter tip located in a stable position in
the endoleak nidus, a microcatheter is advanced into the
endoleak. If feeding vessels are visualised and can be
catheterised, these should be embolised first with coils, a
liquid embolic or small plugs. It may not be possible to
access any feeding arteries, and strenuous and lengthy
efforts should not be made to do this as embolisation of the
nidus is the main aim of this procedure. After embolisation
of any feeding arteries, the nidus is embolised with a liquid
embolic, coils or a combination (Fig. 4).
Outcomes of Direct Sac Puncture Embolisation: There
are only two papers that have specifically reported the
outcomes of direct sac puncture embolisation [56, 57]. In
the larger of these studies, Zener et al. (2018) reported on
33 transabdominal embolisations in 30 patients using a
range of embolic agents with a technical success rate of
97% and clinical success of 85%, defined as freedom from
sac growth (Table 4).
There are several papers that report outcomes comparing
direct sac puncture and transarterial embolisation [58–62].
Recently a systematic review of 32 studies comprising 393
interventions for type II endoleak, compared outcomes for
translumbar embolisation and transarterial embolisation.
The review reported that translumbar embolisation had a
higher technical success rate (81% vs. 63%), fewer cases of
endoleak recurrence (19% vs 36%) and a lower compli-
cation rate (0% vs 9%) when compared with transarterial
embolisation [63]. However, this review includes data from
a heterogenous cohort of studies using a variety of tech-
niques and embolic agents conducted retrospectively, and
its overall conclusion that direct sac puncture is more
effective than transarterial embolisation remains open to
question. Clearly, one must remember that many inter-
ventionists select the embolisation method on a case-by-
case basis dependent on the anatomy of the endoleak and
their perception regarding which technique is likely to be
more likely to be successful. Therefore, in the absence of
evidence from randomised studies comparing techniques,
the reviewer must bear this in mind. It is the author’s
opinion, that if an expert interventionist in all methods
selects the specific technique based on the vascular anat-
omy, then the outcomes of a technically complete
embolisation should be comparable, whichever technique
is used.
Transcaval Embolisation
In this technique, transcaval access into the endoleak
cavity is achieved by using an angled-tip catheter and an
angled sheathed needle (e.g. TIPSS set) to penetrate the
IVC wall and enter the endoleak cavity. There is limited
Fig. 4 Direct sac puncture and embolisation of type 2 endoleak.
A Fluoroscopic guided access into the endoleak cavity via 18G Chiba
needle (arrow), using bony landmarks and aortic endograft markers.
B Angiogram via 18G needle confirms endoleak cavity (nidus) and
several exit vessels (arrow heads). C Embolisation of exit vessels with
micro-coils via microcatheter. D Subsequent embolisation of the
endoleak cavity with Onyx
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data on this technique, which is summarised in Table 5.
The largest cohort included 29 patients, reported by Giles
et al. [86], with technical success achieved in 90% and no
significant adverse events, although 5 patients required
reintervention.
Surgery
Surgical options include laparoscopic clipping of the
lumbar or inferior mesenteric arteries, surgical fixation of
the endograft to the aortic wall or open aneurysmectomy.
These are treatments of last resort for cases where the
above techniques have been unsuccessful or not feasible. In
view of the increasing variety of embolisation techniques
available, surgical intervention is seldom required.
Selecting the Best Approach to Manage Type 2
Endoleaks
As described, there is a range of embolisation techniques
that may be utilised for EL2. In some cases, more than one
technique may be undertaken to achieve embolisation.
Figure 5 illustrates a summary of the author’s practice in
managing EL2.
In principle, when faced with a suspected EL2 and
increasing sac size, it is imperative to consider the possi-
bility of an occult type 1 or type 3 endoleak disguised as a
type 2 endoleak, where opacified aortic side branches are
acting as exit vessels rather entrance vessels. CT imaging is
usually sufficient for this, but if CTA is inconclusive,
catheter aortography (sometimes combined with cone-
beam CT) can be used to help confirm the source of the
endoleak and to plan treatment. Contrast-enhanced ultra-
sound enables real-time imaging of arterial flow into the
endoleak and can be useful as a problem solving tool,
particularly for assessment of the type and anatomy of
endoleaks.
A catheter angiogram with a view to direct transarterial
embolisation is usually the first intervention. If the endo-
leak is arising from retrograde flow in the IMA, a direct
coaxial microcatheter catheterisation via the SMA is usu-
ally feasible. Endoleaks arising from a lumbar or iliolum-
bar branch are often less amenable to transarterial
embolisation than IMA embolisation. Nevertheless,
transarterial embolisation of a lumbar EL2 should be still
attempted at the time of the diagnostic catheter angiogram.
If transarterial embolisation is unsuccessful, a transiliac
paraendograft catheterisation of the endoleak sac can be
attempted during the same sitting. If these are unsuccessful,
consideration should be given to utilising the alternative
access routes of percutaneous direct sac puncture or the
transcaval route. It is the author’s preference to schedule
these at a later date as a separate procedure.
3. Type 3 Endoleaks
Type 3 endoleaks result from a structural defect of the
endograft, and can be subdivided into EL 3a, caused by
component modular disconnection and EL 3b, secondary to
a fabric tear. They are relatively uncommon, and increas-
ingly so with modern stent graft designs. A recent retro-
spective study of 967 EVAR cases reported type 3
endoleaks in 12.7% for first and second generation endo-
grafts and 1.3% in third generation endografts [64]. These
are high flow endoleaks similar to type 1 endoleaks,
resulting in sac pressurisation and therefore EL3 mandate
immediate treatment. The standard treatment is relining the
endograft by deploying a new endograft within the preex-
isting graft. There are a few isolated case reports of
embolisation of EL3 where relining is not possible or fails.
4. Type 5 Endoleaks
These are also termed ‘endotension’ and are defined as
an increase in sac size in the absence of an identifiable
endoleak. When assessing potential cases, catheter
angiography together with cone beam CT may be useful in
excluding the presence of an endoleak or another cause for
sac expansion. If no cause is found, observation may be a
valid option for some of these cases, as these endoleaks are
not directly associated with high pressure, but the criteria
for conservative management are unclear [36]. Options for
intervention in cases of increasing aneurysm sac size
include the use of extension cuffs, relining the endograft
and conversion to open repair [65].
Table 4 Main publications directly assessing outcomes of direct sac puncture and embolisation for EL2
Authors No. of
endoleak
cases
Patient
population
Embolic material Technical
success
(%)
Follow-up
length mean–
months (range)
Clinical
success
(%)
Transabdominal
or Translumbar
Zener et al.
[56]
33 30 Glue only (45.5%), glue/coils (36.4%)
and Onyx with or without glue/coils
(18.1%)
29 (97) 15 23/27 (85) All
transabdominal
Carrafiello
et al.
[57]
8 8 Thrombin only in 5 cases, thrombin
and glue in 2 cases and Onyx in 1
case
8 (100) 36 (24–46) 8 (100) All translumbar
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Table 5 Main publications directly assessing outcomes of transcaval embolisation for EL2
Authors No. of
endoleak
cases
Patient
population
Embolic material Technical
success
(%)
Follow-up length
mean–months
(range)
Clinical
success
(%)
Additional comments
Scali et al.
[84]
6 6 Coils ? thrombin 6 (100) 8.1 (2–22) 4 (66) Thrombin used in 2 IV ultrasound in 4
and intraoperative CT in 2 cases
Gandini
et al.
[85]
29 26 Coils ? glue/
thrombin
9 (100) 25 (14–31) 25 (86) Feeding artery also embolised in 20
cases, all with no recurrence
Giles
et al.
[86]
29 29 Coils ? thrombin 24 (83) 16.5 (± 10.4) 20 (70) Thrombin injection used in 5, IV
ultrasound in 4 and intra operative
CT in 5 cases
Mansueto
[87]
12 12 Coils ? thrombin 11 (92) 12 10 (83) Thrombin injection used in 5, IV
ultrasound in 4 and intra operative
CT in 5 cases
Type 2 endoleak 
confirmed on CT 
angiogram
Stable sac size
No interven n.
Con nued 
surveillance.
Sac size increase 
>5mm
Exclude type 1 and 3 
endoleak 
if necessary using 
catheter angioography 
+/- cone beam CT
Direct transarterial route 
to endoleak
Conven onal 
transarterial 
embolisa on Transiliac paraendogra  
embolisa on
Direct sac puncture or 
transcaval embolisa on
Fig. 5 Summary of author’s
approach to management of
type 2 endoleaks
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Management of Secondary Endoleaks—TEVAR
Thoracic aortic aneurysms (TAAs) affect 10.4 in 100,000
people per year, with an estimated incidence of rupture and
dissection at 3.5 per 100,000 per year, with a high (90%)
mortality rate in cases of acute rupture [66, 67] The aim of
TEVAR is to reduce these risks and many studies have
confirmed favourable long-term outcomes after endovas-
cular repair. Overall, all types of endoleaks after TEVAR
range occur in 9.5 to 15.8% of procedures, and there are
limited data regarding the incidence of secondary vs pri-
mary endoleaks. Below we provide an overview of the
management of endoleaks following TEVAR for aneur-
ysms and do not address those performed for aortic
dissections.
• Type 1a Endoleaks
Type 1 endoleak occurs in 3 to 16% of cases [68–71].
The treatment options are mostly endovascular with a low
rate to open conversion of 3.6% [72]. Secondary proximal
type 1 endoleaks are due to an ongoing poor seal at the
proximal attachment site, dilatation of the proximal
attachment site or distal endograft migration. Management
of secondary EL1a is primarily by extension proximally of
endograft coverage by additional endografts to achieve a
seal. There are a few reports of the use of EndoAnchors to
treat proximal type 1 endoleaks [73, 74]. However, in
general, proximal endograft coverage is the optimal treat-
ment method. If the proximal landing zone is close to or
involves the aortic arch arteries, efforts should be made to
preserve flow into these arteries by surgical debranching,
fenestrations, branches or chimneys. A comprehensive
discussion of these advanced techniques is provided in the
article entitled ‘‘Various endoluminal approaches available
for treating pathologies of the aortic arch’’.
There are a few reports of the use of embolisation to
treat EL1a where other techniques are not feasible and
consideration to this option should be given if the requisite
interventional skills are available for this highly challeng-
ing treatment option. Although the published data are
limited to case reports, the procedural outcomes have been
satisfactory. Day et al. reported two cases of successful
EL1a embolisation post-TEVAR and with no recurrence at
the 12 months follow-up [75]. The technique involves
common femoral artery access, the use of a long sheath to
access the proximal aorta, and a reverse curve-shaped
catheter to engage the endoleak cavity.
Depending on the anatomy of the endoleak, detachable
coils, a liquid embolic agent (e.g. Onyx) or a combination
can be used to occlude the endoleak; however, the risk of
embolisation to the cerebral arteries, especially when using
liquid embolics should be considered. In certain cases, if
the endoleak cannot be accessed from the aortic lumen,
direct percutaneous access [76, 77] can be used. Patients
who cannot be treated by endovascular or surgical methods
are managed conservatively, with the risk of rupture that
this entails.
• Type 1b Endoleaks
Similarly to EL1a, EL1b are treated by distal endograft
extension. If this involves extending across the upper
abdominal visceral arteries, this can be achieved in asso-
ciation with surgical debranching (hybrid procedure),
FEVAR, BEVAR and ChEVAR. There are a few reports of
embolisation of EL1b after TEVAR, and an example is
shown in Fig. 6.
Patients with chronic dissection who develop late false
lumen expansion and require endograft extension distally
can also be treated in this way, although there are also
options for endovascular occlusion of the false lumen using
techniques such as the Candy-Plug procedure, Knicker-
bocker procedure, and embolisation of the false lumen with
coils and liquid embolics. Refer to the article entitled
‘‘Role of endoluminal techniques in the management of
chronic type B aortic dissection’’ in this special issue.
• Type 2 Endoleaks
Type 2 endoleaks after TEVAR result from retrograde
flow into the aneurysm sac from branches of the thoracic
aorta, but are less common compared to EVAR, with a
reported incidence of 3.3% in the EUROSTAR Registry
[78]. The most common cause of an EL2 post-TEVAR is
retrograde flow from the left subclavian artery in patients
where stent grafts have been placed across the origin of the
left subclavian artery. If there is an increase in sac size, the
proximal subclavian artery should be embolised with a
plug or coils from the ipsilateral brachial or radial artery
access, taking care to avoid the origin of the left vertebral
artery, so that perfusion to the left arm via the left vertebral
artery is preserved.
Type 2 endoleaks may also arise from other branches of
the thoracic aorta such as the intercostal and bronchial
arteries. These are usually managed conservatively, unless
there is an increase in the sac size that can only be
attributed to the EL2 [72]. Although challenging to treat,
embolisation of these EL2 may be feasible by the
transarterial or percutaneous direct sac puncture route,
although reports of the efficacy of these techniques are very
limited.
Secondary Endoleak Management Following TEVAR and EVAR
123
Conclusion
Secondary endoleaks remain an ongoing challenge fol-
lowing endovascular repair of the thoracic and abdominal
aorta, mandating a significant burden for healthcare pro-
viders and patients in terms of surveillance and reinter-
vention. Type 1 and 3 endoleaks result from direct
communication between the high-pressure intraluminal
flow in the aortoiliac vessels and the aortic sac. The sig-
nificance of these is well understood, requiring prompt
treatment, which includes endovascular and surgical
options. Type 2 endoleak management remains a subject of
debate however, with embolisation as the mainstay treat-
ment reserved for persistent cases with a significant sac
size increase.
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